TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01923454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paracentesis
Description: At presentation, patients received immediate anterior chamber paracentesis with a 30-gauge needle. The intraocular pressure (IOP) was recorded at immediately, 15 and 30 minutes, and then 1, 24 and 48 hours after paracentesis. The IOP was compared between before paracentesis and each time-point after paracentesis. All affected eyes received antiglaucomatous medications 60 minutes after ACP and underwent peripheral iridotomy within 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: All participants will receive oral acetazolamide (250 mg) 1 tablet at 1 hour after paracentesis to lower the intraocular pressure. After that, the dose of acetazolamide will be adjusted according to the level of intraocular pressure. If the eye pressure goes to normal (lower than 21 mmHg), acetazolamide will be discontinued.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral iridotomy
Description: All affected eyes underwent laser peripheral iridotomy within 24 hours after presentation. This procedure is a standard treatment for acute angle-closure. The fellow eyes will receive laser peripheral iridotomy in the same occasion or later to prevent acute angle-closure in the future.
Study: NCT02214745

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire developed for this purpose by the investigators

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire developed for this purpose by the investigators

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire developed for this purpose by the investigators

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire developed for this purpose by the investigators
Study: NCT01105429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Oral Solution, Oral, 0.3 mg, once daily, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Oral Solution, Oral, 1.0 mg, once daily, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Oral Solution, Oral, 3 mg, once daily, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Oral Solution, Oral, 10 mg, once daily, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Oral Solution, Oral, 30 mg, once daily, 1 day
Study: NCT01110382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route-intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after meropenem placebo for up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem placebo
Description: Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Type=once every 8 hours infused over 30 minutes, Unit=mg, Number=20 mg/kg to 1 gram per dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv meropenem administered every 8 hours immediately before doripenem placebo for up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem placebo
Description: Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately after each iv infusion of meropenem for up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate potassium
Description: Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or meropenem.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate potassium
Description: Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or meropenem.
Study: NCT00265018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adriamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Study: NCT03574740

Intervention type: OTHER
Intervention: Tobacco Smoking
Description: Influence of Tobacco Smoking on the development of OSA
Study: NCT00265018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 30 Gy IF-RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 30 Gy IF-RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 20 Gy IF-RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 20 Gy IF-RT
Study: NCT03519061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Nasal saline irrigations with budesonide
Study: NCT02580786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding peer support
Study: NCT01714258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac output measurement
Description: non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients
Study: NCT01105429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Oral Solution, Oral , 75 mg, once daily, 1 day
Study: NCT03420105

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological, psycho-pathological and quality of life assessments
Description: Patients and Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological, psycho-pathological and quality of life assessments
Description: Patients and Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological, psycho-pathological and quality of life assessments
Description: Patients and Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests

Intervention type: DRUG
Group type: OTHER
Intervention: Hormonotherapy
Description: Adjuvant hormone therapy
Study: NCT02738333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT01802333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT03166605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone
Description: Giving simethicone before and after capsule ingestion.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Simethicone
Description: Giving simethicone before and after capsule ingestion.
Study: NCT02110407

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: transcranial direct current stimulation (tDCS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: transcranial direct current stimulation (tDCS)
Study: NCT01267175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X54 insulin pump with low suspend feature
Description: Change from current insulin pump to new X54 pump
Study: NCT02738333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)
Study: NCT00278109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: doxorubicin
Study: NCT03576313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine (DP)
Description: DP will be available as tablets of 320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight. DP will be taken orally with water and without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin (IVM)
Description: IVM will be available as tablets of 3mg or 6mg strength. It will be given at 300-400μg/kg/day over 3 days (to the nearest whole tablet). IVM will also be taken on an empty stomach with water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard malaria control interventions only
Description: this is the standard malaria control interventions in the Gambia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard malaria control interventions only
Description: this is the standard malaria control interventions in the Gambia
Study: NCT04528056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Sulfasalazine is an anti-inflammatory and immunosuppressive drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Sulfasalazine is an anti-inflammatory and immunosuppressive drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambrisentan
Description: Ambrisentan is one of the specific drug therapy for pulmonary arterial hypertension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfasalazine's placebo
Description: Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage
Study: NCT00278109

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: radiation
Study: NCT04528056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine's placebo
Description: Sulfasalazine's placebo is similar to Sulfasalazine in form and dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan's placebo
Description: Ambrisentan's placebo is similar to Ambrisentan in form and dosage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ambrisentan's placebo
Description: Ambrisentan's placebo is similar to Ambrisentan in form and dosage
Study: NCT04104880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: Adults previously diagnosed with obstructive sleep apnoea will receive a three-month CPAP intervention
Study: NCT00922805

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: guar gum
Description: guar gum (20 g/l of formula) for one week

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: guar gum
Description: guar gum (20 g/l of formula) for one week
Study: NCT01423916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-34712 (4mg)
Description: Arms assigned to this intervention receive 4mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Arms assigned to this intervention will receive 400mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Arms assigned to this intervention will receive 400mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-34712 (12mg)
Description: Arms assigned to this intervention receive 12mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: OPC-34712 placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: OPC-34712 placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: OPC-34712 placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: OPC-34712 placebo
Study: NCT02414620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generation II Dental Vibe Unit
Description: . The Dental Vibe emits strong pulsed vibration which is transmitted via a silicone mouth piece to mucosal tissue.
Study: NCT02553538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Navigators utilized TopCare to track participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
Study: NCT02133365

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness and Interoceptive Exposure
Description: The Mindfulness and Interoceptive Exposure intervention will be delivered in 4-5 manualized, individualized therapy sessions, of 1.5 hours - 2 hours each. The intervention is comprised of four established cognitive-behavioral strategies: psychoeducation, mindfulness, interoceptive exposure and skills generalization.
Study: NCT02087722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KI1001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04035746

Intervention type: OTHER
Intervention: Observation of microcirculation and plasticity of the brain
Description: Assessment of microcirculation, brain plasticity and clinical function
Study: NCT03191253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medically-appropriate meals and groceries
Description: Full nutrition Intervention Components: (1) 7 pre-packaged frozen meals; (2) Groceries or another 7-pack of meals; (3) Nutritional supplement bag to round out the nutrition in terms of nutrients, or dietary reference intakes (DRIs), and number of servings from fruits/vegetables, whole grains, legumes, nuts/seeds and dairy. The nutritional supplemental bag will also contain bulk ingredients to aid in cooking e.g., cooking oil, spices, and herbs as well as bulk items e.g., jar of peanut butter, quart of milk; (4) Individual nutritional counseling (x2 sessions); and (5) Group nutrition education classes (X3 classes) by POH registered dietitian (RD) team.
Study: NCT01032824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Telephone Counseling Intervention
Description: 10-session, 5-month HIV adherence and chronic disease self-management individual telephone counseling intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Group Arm
Description: 10-session didactic telephone group

Intervention type: OTHER
Group type: OTHER
Intervention: Book Arm
Description: Book only.
Study: NCT03665116

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: L-arginine capsule
Study: NCT02924740

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Training
Description: Pelvic floor muscle training consist of fast (2 second) and slow contractions (5-s contraction, 10-s hold, 5-s relaxation, totally 20-s). One set of exercises includes ten fast and ten slow voluntary PFM contractions (VPFMCs). During week 1 and 2, participants will be instructed to perform two sets of exercises per day (20 fast and 20 slow contractions per day), which was progressively increased by two sets: four sets per day at week 3 and 4 (40 fast and 40 slow contractions per day); six sets per day at week 5 and 6 (60 fast and 60 slow contractions per day); eight sets per day at week 7 and 8 (80 fast and 80 slow contractions per day); ten sets per day from week 9 to week 12 (100 fast and 100 slow contractions per day).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training
Description: Pelvic floor muscle training consist of fast (2 second) and slow contractions (5-s contraction, 10-s hold, 5-s relaxation, totally 20-s). One set of exercises includes ten fast and ten slow voluntary PFM contractions (VPFMCs). During week 1 and 2, participants will be instructed to perform two sets of exercises per day (20 fast and 20 slow contractions per day), which was progressively increased by two sets: four sets per day at week 3 and 4 (40 fast and 40 slow contractions per day); six sets per day at week 5 and 6 (60 fast and 60 slow contractions per day); eight sets per day at week 7 and 8 (80 fast and 80 slow contractions per day); ten sets per day from week 9 to week 12 (100 fast and 100 slow contractions per day).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaginal Tampon Training
Description: Vaginal tampon training will be applied for 5 days a week for 12 weeks. Exercises with tampons will be performed two days a week by physiotherapist (first author) and three days a week by patients. One set of tampon exercises consist 15 contractions. During vaginal tampon training, from week 1 to week 12, patients were instructed to perform two sets of exercises for five days a week (two days by physiotherapist, three days by themselves).
Study: NCT02747511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00110461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Treatment Arm 1 (10 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, and aripiprazole 10 mg QD as the target dose starting on Day 5. Subjects remained on the 10 mg dose for the remainder of the treatment period Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Treatment Arm 2 (30 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, aripiprazole 10 mg QD for 2 days, aripiprazole 15 mg QD for 2 days, aripiprazole 20 mg QD for 2 days, aripiprazole 25 mg QD for 2 days, and aripiprazole 30 mg QD as the target dose starting on Day 13. Subjects remained on the 30 mg dose for the remainder of the treatment period. Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet
Study: NCT00724529

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.

Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.
Study: NCT02929212

Intervention type: OTHER
Group type: OTHER
Intervention: Solid Meal
Description: Subjects will receive solid meals during meal study

Intervention type: OTHER
Group type: OTHER
Intervention: Solid Meal
Description: Subjects will receive solid meals during meal study

Intervention type: OTHER
Group type: OTHER
Intervention: Liquid Meal
Description: Subjects will receive liquid meals, during meal study

Intervention type: OTHER
Group type: OTHER
Intervention: Liquid Meal
Description: Subjects will receive liquid meals, during meal study

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: All subjects given acetaminophen to measure gastric emptying

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: All subjects given acetaminophen to measure gastric emptying

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: All subjects given acetaminophen to measure gastric emptying

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: All subjects given acetaminophen to measure gastric emptying

Intervention type: OTHER
Group type: OTHER
Intervention: Single, 600 kcal meal
Description: Subjects will receive a single, 600 kcal meal during meal study

Intervention type: OTHER
Group type: OTHER
Intervention: Single, 600 kcal meal
Description: Subjects will receive a single, 600 kcal meal during meal study

Intervention type: OTHER
Group type: OTHER
Intervention: Multiple, 200 kcal meals
Description: Subjects will receive three, 200 kcal meals, during meal study

Intervention type: OTHER
Group type: OTHER
Intervention: Multiple, 200 kcal meals
Description: Subjects will receive three, 200 kcal meals, during meal study
Study: NCT02773654

Intervention type: OTHER
Intervention: Healthy Volunteers
Description: Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
Study: NCT04076995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Intake
Description: Increased water intake during the 11 h protocol
Study: NCT02110407

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: training
Description: intensive training of visual-spatial abilities (in LOCATO task)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training
Description: intensive training of visual-spatial abilities (in LOCATO task)
Study: NCT01009645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fact Only Education Message
Description: Participants randomized to this intervention will receive an educational brochure listing the facts of the influenza vaccine.
Study: NCT02773654

Intervention type: OTHER
Intervention: Symptomatic Volunteers
Description: Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.